Vice President, Corporate Development
Mori joined Yamanouchi – merged with Fujisawa in 2005 to create Astellas – in 2002 as a researcher, and has since held roles of increasing responsibility in product and portfolio strategy, as well as in Astellas' Pharmaceutical Research & Technology Labs. In 2015, Mori was named associate director of product portfolio and strategy, new product business strategy, where she led the successful strategic analysis and valuation of Astellas’ acquisition of Ocata Therapeutics. Most recently, Mori served as senior strategy and policy staff to global President and CEO Yoshihiko Hatanaka.
Mori is a licensed pharmacist and holds a master's in clinical pharmacy from the Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.